

Carbon Reduction Plan

Company name: Sharpak Healthcare Ltd

Reporting period: 1 January 2025 – 31 December 2025

1. Commitment to Achieving Net Zero

Sharpak Healthcare Ltd is committed to achieving Net Zero emissions by 2040 across Scope 1, Scope 2 and all relevant Scope 3 emissions. The target applies at a global boundary, covering all Sharpak Healthcare Ltd operations and value-chain emissions wherever they occur, using the operational control approach. All of our operations are currently located in the United Kingdom.

This accelerated target is five years ahead of the NHS 2045 ambition for the emissions it influences and aligns with the NHS Net Zero Supplier Roadmap and the wider UK environmental agenda. As a manufacturer of critical healthcare products, we recognise our responsibility to follow a Responsible Pathway to Net Zero that supports the NHS in meeting its own climate ambitions.

2. Baseline Emissions Footprint

Baseline emissions represent the greenhouse gases generated prior to implementing our carbon reduction strategies. Our Scope 1 and 2 baseline year is 2021. Our Scope 3 baseline year is 2025, the year of our first full Scope 3 inventory.

Emissions	Baseline year	Total (tCO ₂ e)
Scope 1	2021	960.45
Scope 2 (market-based)	2021	373.15
Scope 2 (location-based)	2021	406.10
Scope 3 (all relevant categories – see Section 3A)	2025	1,560.67
Total Scope 1 & 2 baseline (market-based)	2021	1,333.60

Note: Scope 3 emissions were not quantified in 2021. This gap was addressed with the completion of a full Scope 3 inventory for 2025, which now forms our Scope 3 baseline.

3. Current Emissions Reporting (2025)

Sharpak Healthcare reports Scope 1, Scope 2 (both market-based and location-based) and Scope 3 emissions in accordance with the Greenhouse Gas Protocol and the NHS Evergreen reporting requirements.

Source	Emissions (tCO ₂ e)
Scope 1	31.12
Scope 2 (market-based)	0.00
Scope 2 (location-based)	259.94
Scope 3 (all relevant categories)	1,560.67
Total emissions (market-based Scope 2)	1,591.79

In 2025, Sharpak Healthcare achieved zero market-based Scope 2 emissions for the fourth consecutive year through continued use of certified renewable electricity. Location-

based emissions remain measurable due to the carbon intensity of the UK grid. Scope 1 emissions are 96.8% below the 2021 baseline.

3A. Scope 3 Emissions Reporting (2025)

Sharpak Healthcare completed its first full Scope 3 greenhouse gas inventory for 2025, covering all relevant value-chain categories in accordance with the GHG Protocol Corporate Value Chain (Scope 3) Standard. Product-related emissions are based on a cradle-to-grave Life Cycle Assessment (LCA) prepared by Tunley Environmental using a methodology consistent with ISO 14067:2018, applied to 2025 sales volumes and allocated to GHG Protocol categories using the LCA's life-cycle stage results.

Manufacturing energy within the LCA (8.69 tCO₂e) is excluded from Scope 3, as it is already reported in Scope 1 and 2.

GHG Protocol category	Description	Emissions (tCO ₂ e)	% of Scope 3
Cat 1	Purchased goods: embodied carbon of raw materials (PP/HDPE) and components	1,158.27	74.22%
Cat 4	Upstream transportation and distribution of raw materials	281.76	18.05%
Cat 9	Downstream transportation and distribution of products to customers	28.01	1.79%
Cat 12	End-of-life treatment of sold products: packaging waste, collection and clinical waste incineration	51.30	3.29%
Cat 3	Fuel- and energy-related activities (well-to-tank electricity) not included in Scope 1 & 2	24.72	1.58%
Cat 5	Waste generated in operations (26.0 t: plastic and cardboard recycled, general waste to energy recovery; zero to landfill)	0.12	0.01%
Cat 6	Business travel (air and road)	3.12	0.20%
Cat 7	Employee commuting	13.37	0.86%
Total	Total Scope 3 emissions (2025)	1,560.67	100%

All Scope 3 categories required under PPN 006 are reported: upstream transportation and distribution (Cat 4), waste generated in operations (Cat 5), business travel (Cat 6), employee commuting (Cat 7) and downstream transportation and distribution (Cat 9).

Categories not reported: Cat 8 Upstream leased assets, Cat 13 Downstream leased assets, Cat 14 Franchises and Cat 15 Investments are not applicable, as Sharpak Healthcare has no leased assets, franchises or investments. Cat 10 Processing of sold products is not applicable, as products are sold as finished goods requiring no further processing. Cat 11 Use of sold products is not applicable, as sharps containers consume no energy or fuel in use. Cat 2 Capital goods is not relevant for 2025, as Sharpak Healthcare Ltd made no capital goods purchases in the reporting year; it will be reported in any year in which capital purchases are made.

The 2025 Scope 3 assessment confirms that product-related emissions dominate the value chain, accounting for over 97% of total Scope 3 emissions. Embodied carbon in

purchased raw materials is the single largest contributor (74% of Scope 3), followed by upstream transport of materials (18%); end-of-life treatment accounts for around 3%. This dataset forms Sharpak Healthcare's official Scope 3 baseline and will be used to:

- track annual progress against reduction targets;
- support NHS Evergreen reporting;
- identify decarbonisation hotspots;
- inform product design improvements and material selection; and
- guide customer transition to multi-use systems such as the Sharpak Zero range.

4. Emission Reduction Targets

To achieve Net Zero by 2040, Sharpak Healthcare has set the following targets. Residual emissions remaining in the target year will be neutralised through high-quality carbon removals.

Scope	Base year	Target	Target year
Scope 1	2021	Net Zero: at least 95% absolute reduction, with residual emissions (up to 5%) neutralised	2040
Scope 2	2021	100% absolute reduction (market-based) – achieved and maintained through 100% renewable electricity	Achieved 2022; maintained to 2040
Scope 3	2025	Net Zero: at least 90% absolute reduction across all relevant categories, with residual emissions (up to 10%) neutralised	2040
Scope 3 (near-term)	2025	20% reduction in Scope 3 emissions intensity per unit sold	2030

Supporting commitments:

- Scope 1: sustain the 96.8% reduction achieved since 2021 by keeping carbon-intensive fuels out of our operations.
- Energy intensity: continue improving operational efficiency through investment in modern, energy-efficient equipment, reducing location-based Scope 2 emissions.
- Scope 3: drive the near-term reduction through product redesign, higher recycled content and growth of the Sharpak Zero multi-use range, and support NHS partners in moving from single-use to multi-use systems.
- Reporting: reassess Scope 3 annually to track progress, validate reductions and identify emerging hotspots, and maintain compliance with PPN 006 and NHS Evergreen reporting.

Progress to date: Scope 1 and market-based Scope 2 emissions have fallen from 1,333.60 tCO₂e in 2021 to 31.12 tCO₂e in 2025, a reduction of 1,302.48 tCO₂e (97.7%).

5. Carbon Reduction Projects

Completed projects (2021–2025)

The following environmental management measures and projects have been completed and have delivered the Scope 1 and 2 reductions reported above:

- Fuel switching: full elimination of heavy oil by 2022 and significant reductions in natural gas consumption.
- Renewable electricity: 100% renewable electricity (REGO-backed) since 2022, achieving four consecutive years of zero market-based Scope 2 emissions.
- Operational efficiency: upgraded to energy-efficient equipment and improved insulation across our manufacturing site.
- Waste management: achieved and maintained zero waste to landfill.
- Fleet: 75% of company vehicles are fully electric, covering 95% of fleet mileage.

Future initiatives (2026 and beyond)

- Energy-efficient machinery: ongoing capital investment in next-generation injection moulding equipment to reduce grid electricity consumption (location-based Scope 2).
- Sharpak Zero scaling: continuing to expand the multi-use product range to support NHS decarbonisation.
- Supply chain engagement: enhanced supplier assessments to improve Scope 3 data quality and collaborate on emissions reduction.
- Scope 3 data: review capital goods (Cat 2) relevance annually and increase the use of supplier-specific data in the 2026 inventory.
- Scope 3 reduction projects:
 - Product value chain (97% of Scope 3): expansion of the Sharpak Zero multi-use range to progressively replace single-use products.
 - Operational value chain (1.6%): investigation of on-site solar PV to reduce well-to-tank electricity emissions.
 - Travel and commuting (1%): further development of EV charging infrastructure at Sharpak sites.

6. Methodology and Reporting Standards

- Standards: GHG Protocol Corporate Accounting and Reporting Standard; GHG Protocol Corporate Value Chain (Scope 3) Standard; ISO 14067:2018 for product carbon footprints.
- Organisational boundary: operational control; global boundary covering all operations (currently all located in the United Kingdom).
- Reporting period: 1 January 2025 to 31 December 2025 (calendar year).
- Emission factors: UK Government GHG Conversion Factors for Company Reporting (DESNZ/DEFRA) 2025; waste disposal factors from the 2026 edition.
- Data sources: utility invoices, fuel records, mileage logs and travel records; staff commuting data; product LCA data prepared by Tunley Environmental.

7. Declaration and Sign-off

This Carbon Reduction Plan has been completed in accordance with PPN 006 and associated guidance and reporting standard for Carbon Reduction Plans.

Emissions have been reported and recorded in accordance with the published reporting standard for Carbon Reduction Plans and the GHG Reporting Protocol corporate standard, and use the appropriate Government emission conversion factors for greenhouse gas company reporting. Scope 1 and Scope 2 emissions have been reported in accordance with SECR requirements, and the required subset of Scope 3 emissions has been reported in accordance with the published reporting standard for Carbon Reduction Plans and the Corporate Value Chain (Scope 3) Standard.

This Carbon Reduction Plan has been reviewed and signed off by the Board of Directors of Sharpak Healthcare Ltd.

Signed on behalf of Sharpak Healthcare Ltd:



Henry Powell, Commercial Director

27 October 2026

Document Control

Issue	Date	Summary of changes
1	March 2026	First publication.
2	August 2026	Updated with 2025 emissions and first full Scope 3 inventory.
3	October 2026	Net Zero target confirmed as covering Scopes 1, 2 and 3 at a global boundary; targets set out by scope; Scope 2 location-based baseline added; all relevant Scope 3 categories reported by GHG Protocol category, including waste (Cat 5), with exclusions explained; manufacturing energy double count removed from Scope 3; methodology section added; declaration updated to PPN 006 with Board sign-off.